

**ESOPHAGOGASTRIC
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION**

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO

DATE SATURDAY, MAY 2nd, 2015

TIME: 14:00 – 15:15

CHAIRS: DR. REBECCA WONG & Dr. CHRISTIAN KOLLMANSBERGER

| | | |
|-------|---|-----------------------------------|
| 14:00 | WELCOME & INTRODUCTION | |
| 14:00 | ACTIVE TRIALS | |
| | GA.1 (TOP GEAR): A RANDOMIZED PHASE III TRIAL OF PREOPERATIVE CHEMORADIOTHERAPY VERSUS PREOPERATIVE CHEMOTHERAPY FOR RESECTABLE GASTRIC CANCER | DR. R. WONG/DR. G. DARLING |
| 14:20 | GUEST PRESENTATION – PHASE II RESULTS AND PHASE III PROPOSAL | |
| | GA.2 (INTEGRATE): A RANDOMISED PHASE II DOUBLE-REGORAFENIB OR PLACEBO IN REFRACTORY ADVANCED ESOPHAGO-GASTRIC CANCER (AEGC) | DR. K. SJOQUIST |
| | INTEGRATE II TRIAL PROPOSAL | DR. K. SJOQUIST |
| 14:55 | TRIAL PROPOSALS/CONCEPTS IN DEVELOPMENT – COMPOUNDS OF INTEREST? | |
| | ASTRAZENECA MEDI4736 / BIOTHERA IMPRIME PGG | DR. R. WONG |
| 15:05 | INTERGROUP TASK FORCE UPDATE | DR. R. WONG |
| | CLOSING REMARKS | |